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Abstract
Alzheimer’s disease is characterized by accumulation of amyloid plaques and tau aggregates in several cortical brain
regions. Tau phosphorylation causes formation of neurofibrillary tangles and neuropil threads. Phosphorylation at tau
Ser202/Thr205 is well characterized since labeling of this site is used to assign Braak stage based on occurrence of
neurofibrillary tangles. Only little is known about the spatial and temporal phosphorylation profile of other
phosphorylated tau (ptau) sites. Here, we investigate total tau and ptau at residues Tyr18, Ser199, Ser202/Thr205, Thr231,
Ser262, Ser396, Ser422 as well as amyloid-β plaques in human brain tissue of AD patients and controls. Allo- and
isocortical brain regions were evaluated applying rater-independent automated quantification based on digital image
analysis. We found that the level of ptau at several residues, like Ser199, Ser202/Thr205, and Ser422 was similar in healthy
controls and Braak stages I to IV but was increased in Braak stage V/VI throughout the entire isocortex and transentorhinal
cortex. Quantification of ThioS-stained plaques showed a similar pattern. Only tau phosphorylation at Tyr18 and Thr231
was already significantly increased in the transentorhinal region at Braak stage III/IV and hence showed a progressive
increase with increasing Braak stages. Additionally, the increase in phosphorylation relative to controls was highest at
Tyr18, Thr231 and Ser199. By contrast, Ser396 tau and Ser262 tau showed only a weak phosphorylation in all analyzed
brain regions and only minor progression. Our results suggest that the ptau burden in the isocortex is comparable
between all analyzed ptau sites when using a quantitative approach while levels of ptau at Tyr18 or Thr231 in the
transentorhinal region are different between all Braak stages. Hence these sites could be crucial in the pathogenesis of AD
already at early stages and therefore represent putative novel therapeutic targets.
Keywords: Microtubule-associated protein tau, Phosphorylation, Cingulate, Frontal, Occipital and temporal cortex,
Transentorhinal region, Immunofluorescent labeling
Introduction
Alzheimer’s disease (AD) is neuropathologically char-
acterized by two hallmark lesions, which are extracel-
lular amyloid-β (Aβ) plaques and intracellular
accumulations of abnormally phosphorylated tau. Aβ
plaques initially develop in neocortical regions and
then progress to the limbic system, subcortical nuclei
and reach the cerebellum at late stages of the disease
[41]. Tau pathology manifests as neurofibrillary tan-
gles (NFTs) and neuropil threads (NTs) and primarily
accumulates in the entorhinal region and subse-
quently progresses to the limbic system and
neocortical regions as reflected by NFT Braak stages
[8]. Tau aggregation depends on several posttransla-
tional modifications, including but not limited to,
truncation, acetylation, ubiquitination, sumoylation
and phosphorylation [13, 29, 34]. The best analyzed
posttranslational modification in AD is abnormal
phosphorylation of tau which in AD is referred to as
hyperphosphorylation and that is characterized by an
at least 3-fold increase of tau phosphorylation relative
to controls. Over 70 potential tau phosphorylation
(ptau) sites spanning almost the entire protein struc-
ture and including some phosphorylation sites are as-
sumed to be pathologically relevant [40]. Some of
these ptau sites are known to be abnormally phos-
phorylated in paired helical filaments (PHFs), NFTs or
NTs during progression of AD but are not
* Correspondence: birgit.hutter-paier@qps.com
1QPS Austria GmbH, Neuropharmacology, Parkring 12, 8074 Grambach,
Austria
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Neddens et al. Acta Neuropathologica Communications  (2018) 6:52 
https://doi.org/10.1186/s40478-018-0557-6
phosphorylated in healthy brains [10, 15, 22, 26, 28].
Several of these ptau sites are also phosphorylated in the
fetal brain and are thus associated with embryonic brain
developmental processes [10, 15, 22]. In the diseased
brain, ptau sites are commonly associated with tau aggre-
gation processes such as incomplete binding and
destabilization of microtubules, causing the transition
from pre-tangles to NFT formation [12, 16, 21, 28, 32].
The temporal and spatial phosphorylation pattern of
tau residue Ser202/Thr205 has already been well charac-
terized since staging of AD cases is based on labeling of
ptau Ser202/Thr205 using the specific antibody AT8 [1,
9, 20, 46]. However, the phosphorylation profile of other
ptau sites known to be involved in AD pathology is so
far strongly neglected and analyzed only by ELISA and
dot blots of AD brain tissue [20, 46].
Phosphorylation at several residues during disease pro-
gression has been repeatedly investigated in tau animal
models but barely in AD brain tissue [4, 7, 14, 20, 46].
Hence, the present study aims to evaluate the spatial
and temporal phosphorylation profile of different tau
sites by applying rater-independent automated quantifi-
cation based on digital image analysis. We therefore
quantified the expression of total tau, amyloid-β plaques
and the phosphorylation of seven different tau sites
(Tyr18, Ser199, Ser202/Thr205, Thr231, Ser262, Ser396,
Ser422) in iso- and allocortical brain regions of AD cases
and controls.
Materials and methods
Human brain samples
Paraffin sections of 6 μm thickness and frozen samples
from AD patients of three different disease stages [Braak
stages I/II, III/IV and V/VI; [9]] and control individuals
with Braak stage 0 were provided by the Newcastle Brain
Tissue Resource (NBTR), Newcastle University, UK in
accordance with the approval of the joint Ethics Com-
mittee of Newcastle and North Tyneside Health Author-
ity and following NBTR brain banking procedures. The
neuropathological diagnosis was performed according to
Table 1 Individual case information. Demographic patient information
Case Age Sex Braakstage Post mortem delay to
fixation in hours
Fixation time in
weeks
Clinical information # on Western
blot
Controls 1 68 M 0 54 7 Cognitively normal 1
2 55 M 0 41 11 Cognitively normal 2
3 70 M 0 72 6 Cognitively normal –
4 78 F 0 34 8 Cognitively normal 4
5 73 M 0 25 9 Cognitively normal –
mean 68.8 0 45.2 8.2
Braak I/II
Low
6 96 F 2 114 49 Mild dementia 6
7 77 M 2 83 15 Cognitively normal 7
8 94 F 2 15 9 Cognitively normal –
9 70 M 2 39 7 Multiple psychiatric and physical
problems
9
10 74 F 1 49 10 Cognitively normal 10
mean 82.2 1.8 60 18
Braak III/IV
Mod.
11 75 M 4 82 23 Cognitively normal 11
12 79 M 3 13 15 Cognitively normal 12
13 81 M 3 82 8 Unspecified dementia 13
14 98 F 3 59 8 Cognitively normal 14
15 91 M 3 48 9 Moderate cognitive impairment and
vascular disease
15
mean 84.8 3.2 56.8 12.6
Braak V/VI
High
16 84 F 6 47 16 Severe dementia, anxiety and
depression
–
17 77 F 6 63 5 Dementia 17
18 80 F 6 32 16 Dementia 18
19 86 F 6 5 6 Dementia 19
20 89 F 6 85 8 Dementia –
mean 83.2 6 46.4 10.2
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internationally accepted criteria [31] (Table 1). Tissue of
one patient of Braak stage V/VI yielded clearly stronger
pathology compared to the other cases, representing an
overshoot outlier. Data of this patient were excluded for
pThr231 calculations. For histological analyses, five cases
per group were investigated using sections of 5 brain re-
gions per individual: temporal cortex (TeCtx), frontal
cortex (FrCtx), cingulate cortex (CiCtx), occipital cortex
(OcCtx), and transentorhinal region (TEntR). All histo-
logical assessments were done blinded to clinical and
neuropathological data.
Immunofluorescent labeling
Sections were deparaffinized for 10 min in Tissue Clear
(Sakura, 1466, Netherlands) and 5 min in Tissue Clear/
100% ethanol, washed for 5 min in 100% ethanol and
then subsequently rehydrated with decreasing alcohol
concentrations (96, 70 and 50% ethanol for 2 min each).
Thereafter, sections were washed twice for 5 min in PBS.
Sections for labeling of human total tau, ThioflavinS
(ThioS), pThr231 tau, pSer199 tau, pTyr18 tau and
pSer396 tau were treated for 15 min with citrate buffer
(Thermo Scientific, AP-9003) at 95 °C in a steamer and
cooled down to room temperature (RT) for another
15 min. For ThioS staining, sections were then labeled
with 0.5% ThioS (Sigma-Aldrich, T1892) for 7 min
under light protection. Afterwards, sections were pre-
treated with ice-cold sodium borohydride/PBS solution
(1 mg/ml; Sigma-Aldrich, 213,462) for 4 min and tissue
was then permeabilized with 1% Triton® X-100/PBS
(AppliChem, A1388) for 10 min. Non-specific labeling
was blocked by incubating sections for 30–60 min either
with 10% donkey serum/PBS or 10% horse serum/PBS.
For antigen detection, sections were incubated with pri-
mary antibodies (Table 2) in a damp chamber. Primary
antibody binding was visualized by incubating sections
with secondary fluorophore conjugated antibodies (Table
3) for 60 min. Furthermore, cell nuclei of tissue labeled
for pSer199 tau, pSer396 tau and pSer422 tau were visu-
alized by counterstaining with 4′,6-Diamidin-2-pheny-
lindol-working solution (DAPI, AppliChem, A1001) for
15 min, differentiated with 70% ethanol and washed for
5 min in PBS. Finally, sections were washed in ddH2O
and covered with Moviol and coverslips.
In order to use the human sections efficiently, double
labelings were performed: pSer202/Thr205 combined
with pSer262 (Additional file 1: Online Source 9); ThioS
combined with HT7; pSer199 combined with pSer396.
Labelings against pTyr18, pThr231 and pSer422 were
performed without co-labeling of another ptau residue.
Imaging and image analysis
Of each labeled brain section two mosaic images with a
size of approximately 3 mm2 including white and grey
matter were captured at different z-levels and finally
projected to 2D.
Imaging of immunofluorescent labelings of pSer202/
Thr205 tau, pSer199 tau, pSer396 tau, pSer262 tau and
pSer422 tau was performed using a Nikon Eclipse E400
microscope with a high aperture lens (20× lens, numer-
ical aperture 0.5, 1× optocoupler), equipped with a
Nikon DS-Qi1MC camera and controlled by the Nikon
NIS-Elements AR software. For quantification of total
human tau, pThr231 tau, pTyr18 tau and ThioS images
were recorded using a Zeiss AxioImager.Z1 microscope
with a high aperture lens and an AxioVision 4.8
software-driven AxioCam MRm digital camera (20×
lens, numeric aperture 0.8, 1× optocoupler).
Quantitative image analysis was performed using
Image-Pro Plus (version 6.2, Media Cybernetics, Inc.,
Rockville, USA). Grey-scale single channel images were
corrected for background intensities using lowpass filter-
ing, and signal from autofluorescent objects (mostly
lipofuscin and erythrocytes) was subtracted from the
channel used for immunofluorescent labeling. Objects
were identified by a combination of Edge+ filter, ad-
equate thresholding, and size and shape restrictions
(Additional file 1: Online Source 10). After defining the
parameters for detecting the targeted objects,
macro-driven quantitative image analysis ran automatic-
ally using the same parameters on all images. The
Table 2 List of primary antibodies for histology
Antigen Clone Species Source Order # Dilution Incubation time
Total human tau HT7 mouse Pierce Biotechnology, USA MN1000 1:500 overnight at 4 °C
pThr231 AT180 mouse Pierce Biotechnology, USA MN1040 1:200 overnight at 4 °C
pSer202 + pThr205 AT8 mouse Thermo Scientific, USA MN1020 1:200 overnight at 4 °C
pSer199 polyclonal rabbit Invitrogen Corporation, USA 44-734G 1:500 1 h at RT
pTyr18 9G3 mouse MédiMabs, Canada MM-0194-P 1:1000 1 h at RT
pSer396 PHF13 mouse Cell Signaling Technology, USA 9632 1:500 1 h at RT
pSer262 polyclonal rabbit MBL International, USA AT-5020 1:250 overnight at 4 °C
pSer422 5.6.11 mouse Roche Diagnostic, Switzerland N/A 1:800 overnight at 4 °C
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quantitative results are therefore unbiased,
rater-independent and fully reproducible.
Preparation of sarcosyl insoluble fraction from frozen
samples
Frozen transentorhinal cortex tissue was homogenized
in 9 μl per mg of cold extraction buffer 1 (25 mM Tris
HCl pH = 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 10 mM ß-glycerophosphate, 30 mM NaF, 2 mM
Na3VO4, protease and phosphatase inhibitor cocktails)
and centrifuged at 80,000 g for 15 min at 4 °C. The pel-
let was resuspended in extraction buffer 2 (10 mM Tris
HCl pH = 7.4, 800 mM NaCl, 300 mM sucrose, 1 mM
EGTA, protease and phosphatase inhibitor cocktails)
and centrifuged at 4000 g for 10 min at 4 °C. The Super-
natant was transferred to a fresh tube and sarcosyl (30%
aqueous solution) was added to a final concentration of
1% and incubated for 1.5 h at room temperature. After
centrifugation at 80,000 g for 30 min at 4 °C, the super-
natant was discarded and the pellet resuspended in buf-
fer 3 (50 mM Tris-HCl, pH = 7.4). The suspension was
aliquoted and frozen until used for Western blotting.
Western blot analyses
Equal amounts of proteins of each brain extract were sep-
arated by molecular weight on a SDS-PAGE polyacryl-
amide gel. A protein marker visualized correct separation
of the proteins and confirmed the correct protein band
size. Subsequently, proteins were transferred onto a
0.45 μm nitrocellulose membrane using a wet blot cham-
ber (Bio-Rad, Hercules, USA), blocked with 5% non-fat
dry milk in 1 × TBS and incubated with primary anti-
bodies overnight. To blot for total tau, pTyr18, and
pSer199 the same primary antibodies as used for histo-
logical labeling were used in a concentration of 1:1000
(Table 2). Antibodies AT180 and AT8 to label pThr231
and pSer202/Thr205, respectively, did not give any signal
in the Western blot and were thus substituted by a rabbit
polyclonal antibody against pThr231 (1:1000; Signalway,
SAB1110–2, College Park, USA) and a rabbit monoclonal
antibody, clone EPR2402, against pSer202/Thr205
(1:3000; abcam, ab108387, Cambridge, UK). All primary
antibodies were incubated for 2 h at room temperature.
Afterwards, membranes were washed in TBS and incu-
bated in horseradish peroxidase-coupled secondary anti-
bodies for 1 h at room temperature (1:5000;
donkey-anti-rabbit IgG: NA934/ GENA934;
sheep-anti-mouse IgG: NXA931; GE-Healthcare, Little
Chalfont, UK). Proteins were detected using
Wester-Bright ECL spray (Advansta, Menlo Park, USA)
and placed on a X-ray film. As loading control a rabbit
polyclonal GAPDH antibody (Sigma-Aldrich, G9545, St.
Louis, USA) was co-labeled on each blot. To blot with 6
different antibodies, three blots were used to prevent false
signals due to stripping, reblotting or blocking of antibody
binding by previously used antibody. For each of the three
blots, GAPDH as loading control is shown. Densitometry
of all bands was performed using Image J software. Cases
3, 5, 8, 16 and 20 according to Table 1 are missing in this
analysis since no frozen tissue was available from the cor-
responding brain region.
Statistical analyses
All statistical analyses and preparation of graphs were con-
ducted using Graph-Pad Prism (version 4.03, San Diego,
CA, USA). Descriptive statistical analyses were performed
on all evaluated parameters including the evaluation of nor-
mal distribution using the Kolmogorov-Smirnov test.
Group variances were calculated either by one-way or
two-way ANOVA. If a significant interaction among
groups was detected, Newman-Keuls or Bonferroni’s
post-hoc analysis was followed. A detailed description of
performed statistical analyses is given in the appropriate
figure legend. Data were averaged and represented as
mean + standard error of mean (SEM). An α-error level of
p < 0.05 was considered significant.
Results
In order to evaluate the overall human tau expression
levels, brain tissues were labeled with the anti-human
Table 3 List of secondary antibodies
Antibody Conjugation Source Order # To visualize
Donkey Anti-Mouse IgG H&L AlexaFluor 555 abcam, UK ab150110 pSer422 tau
pSer396 tau
pSer202/ pThr205 tau
Donkey Anti-Rabbit IgG H&L DyLight 650 abcam, UK ab96922 pSer199 tau
pSer262 tau
Donkey Anti-Mouse IgG H&L DyLight 550 abcam, UK ab98795 pThr231 tau
Donkey Anti-Mouse IgG (H + L) Cyanine Cy3 Jackson ImmunoResearch, USA 715–165-151 Total human tau
Donkey Anti-Mouse IgG H&L DyLight 650 abcam, UK ab98797 pTyr18 tau
Dilution of all secondary antibodies was 1:500
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total tau HT7 antibody. Quantification of the HT7 im-
munoreactive area in the isocortex and transentorhinal
region (TEntR) revealed a progressive increase of total
tau with advancing Braak stages. This increase in total
tau signal was significant at Braak stage V/VI compared
to healthy controls but also compared to both lower
Braak stages I/II and III/IV (Fig. 1a). Data of the isocortex
in Fig. 1a are the mean of four distinct isocortical regions,
namely temporal, frontal, cingulate and occipital cortex.
Separate presentation of these brain regions shows that
total tau expression levels were very low in the cingulate
cortex but relatively high in the occipital cortex of healthy
controls (Fig. 1b). In all isocortical regions total tau levels
started to increase at Braak stage III/IV and were signifi-
cantly higher at Braak stage V/VI compared to controls or
Braak stage I/II. At Braak stage V/VI total tau levels were
highest in the frontal and occipital cortex (Fig. 1b). Since
amyloid-β plaques are, next to tau, a major pathological
hallmark of AD, the ThioflavinS (ThioS) stained area was
quantified in the isocortex and TEntR of AD patients and
healthy controls (Fig. 1c). Threshold-based identification
of ThioS staining combined with a size restriction filter
enabled automatic quantification of plaque cores while
excluding NFTs (Additional file 1: Online Source 11). We
found that ThioS signal was significantly increased in the
isocortex of Braak stage V/VI patients compared to con-
trols and all other Braak stages; a first non-significant in-
crease in the isocortical ThioS signal could be observed at
Braak stage III/IV (Fig. 1c). In the TEntR, ThioS signal
slightly increased at Braak stage III/IV but did not further
increase at Braak V/VI. Almost no ThioS signal could be
observed in the cingulate cortex. In the temporal and
frontal cortex the ThioS signal was very low while only in
the occipital cortex the ThioS signal was well measurable
and progressively increasing starting at Braak stage III/IV
(Fig. 1d).
After evaluating the overall total tau and plaque load,
we measured the phosphorylation levels of ptau at seven
different residues. First, we show phosphorylation of
pSer202/Thr205 tau since this phosphorylation site is
already well characterized and thus can be utilized to
validate the results.
pSer202/Thr205 tau
Phosphorylation of tau at Ser202/Thr205 was low in all
isocortical brain regions up to Braak stage III/IV. Only at
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Fig. 1 Quantification of total human tau and plaque load in the cortex of AD cases. a Total human tau (HT7 antibody) immunoreactive area in
percent in the isocortex and TEntR (allocortex) of different AD stages. c β sheet (ThioflavinS staining) positive area in percent in the isocortex and
TEntR of different AD stages. Isocortical data in a and c present mean of different cortical regions that are shown separately in b and d,
respectively. Two way ANOVA followed by Bonferroni’s posthoc test. Mean + SEM; N = 5.*p < 0.05; **p < 0.01; ***p < 0.001. c, d One outlier of Braak
stage V/VI excluded for all ThioS labelings. Solid lines: Comparison of AD stages within a brain region; dotted lines: comparison of brain regions
of the same AD Braak stage. CiCtx: cingulate cortex; FrCtx: frontal cortex; OcCtx: occipital cortex; TeCtx: temporal cortex; TEntR:
transentorhinal region
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Braak stage V/VI Ser202/Thr205 tau phosphorylation sig-
nificantly increased about 4- to 13-fold above control
levels (Fig. 2a, b). At Braak stage V/VI the highest Ser202/
Thr205 tau phosphorylation could be observed in the tem-
poral cortex while the lowest phosphorylation was in the
cingulate cortex (Fig. 2b). Analysis of the allocortical
TEntR showed a first but not significant pSer202/Thr205
tau increase in Braak stage III/IV that became significant
at Braak stage V/VI (Fig. 2a).
pThr231 tau
Phosphorylation of tau at Thr231 was also low in all
isocortical brain regions up to Braak stage III/IV.
Only at Braak stage V/VI Thr231 tau phosphorylation
significantly increased about 30- to 160-fold above
control levels (Fig. 2c, d). At Braak stage V/VI the
highest Thr231 tau phosphorylation could be ob-
served in the temporal cortex while the lowest phos-
phorylation was in the frontal cortex (Fig. 2d).
Analysis of the allocortical TEntR showed a first but
not significant pThr231 tau increase at Braak stage I/
II that became significant compared to healthy con-
trols at Braak stage III/IV and further significantly in-
creased at Braak stage V/VI compared to all other
groups (Fig. 2c).
pSer199 tau
Overall, phosphorylation of tau at Ser199 was low com-
pared to other phosphorylation sites. In all isocortical re-
gions Ser199 tau phosphorylation started late, namely at
Braak stage V/VI (Fig. 3a, b). At Braak stage V/VI
Ser199 tau phosphorylation was at comparable levels in
all isocortical regions and about 50- (occipital cortex) to
1300-fold (cingulate cortex) increased compared to
healthy controls (Fig. 3b). Analysis of the allocortical
TEntR showed a progressive increase in Ser199 tau
phosphorylation starting at Braak stage I/II but differ-
ences between Braak stages became significant only at
stage V/IV and were then about 3.5-fold compared to
Braak stage III/IV and 160-fold compared to healthy
controls (Fig. 3a). Phosphorylation of Ser199 tau in the
TEntR of late Braak stages was higher compared to all
isocortical regions.
pTyr18 tau
The phosphorylation profile of pTyr18 tau in the isocor-
tex and TEntR was very similar to pSer199 tau although
the final phosphorylation levels in Braak stage V/VI were
slightly higher and increased about 20- to 140-fold above
control levels (Fig. 3c, d). The progression in the TEntR
was already significant at Braak stage III/IV compared to
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Fig. 2 Quantification of tau phosphorylation at pSer202/Thr205 and pThr231 in the cortex of AD cases. a Human pSer202/Thr205 tau
immunoreactive area in percent in the isocortex and TEntR (allocortex) of different AD stages. c Human pThr231 tau immunoreactive area in
percent in the isocortex and TEntR of different AD stages. Isocortical data in a and c present mean of different cortical regions that are shown
separately in b and d, respectively. Two way ANOVA followed by Bonferroni’s posthoc test. Mean + SEM; N = 5.*p < 0.05; **p < 0.01; ***p < 0.001.
Solid lines: Comparison of AD stages within a brain region; dotted lines: comparison of brain regions of the same AD Braak stage. CiCtx: cingulate
cortex; FrCtx: frontal cortex; OcCtx: occipital cortex; TeCtx: temporal cortex; TEntR: transentorhinal region
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stage I/II and controls. At Braak stage V/VI the highest
pTyr18 tau could be observed in the TEntR and cingulate
cortex while the lowest phosphorylation was measured in
the occipital cortex (Fig. 3c, d).
pSer396 tau
Phosphorylation of tau at Ser396 shows higher vari-
ability than other ptau sites. In the isocortex overall
Ser396 tau phosphorylation starts very late in Braak
stage V/VI (Fig. 4b). When analyzing different isocor-
tical regions separately, it seemed that pSer396 tau
was slightly increased in the temporal cortex of
healthy controls and in the cingulate cortex at early
Braak stage I/II but these variations were not signifi-
cant (Fig. 4b). Otherwise, Ser396 tau phosphorylation
in all investigated regions only increased about 2- to
5-fold at Braak stage V/VI compared to control levels.
Due to the high inter-individual variation this difference
was only significant in the temporal cortex compared to
Braak stage I/II and III/IV (Fig. 4b). In the allocortical
TEntR pSer396 tau increased significantly at Braak stage
V/VI compared to all other groups (Fig. 4a).
pSer262 tau
Phosphorylation of tau at Ser262 was very low and showed
almost no progression in higher Braak stages (Fig. 4c). Only
in the TEntR a significant 8-fold increase could be noted
between Braak stage I/II and V/VI (Fig. 4d).
pSer422 tau
The phosphorylation profile of tau at Ser422 was com-
parable in all isocortical regions and also the allocortical
TEntR. In all analyzed regions phosphorylation signifi-
cantly increased at Braak stage V/VI (Fig. 4e, f ) and was
about 3- to 13-fold higher compared to the control
group.
Relative signal increase of ThioS and ptau
When evaluating the signal increase relative to
healthy control brain tissue, it became evident that
ThioS labeling in the TEntR increased already at
Braak stage III/IV and reached a plateau at Braak
stages III/IV and V/VI. The phosphorylation at tau
Tyr18 and tau Ser199 severely increased at the same
time at Braak stage V/VI with already a slight in-
crease at Braak stage III/IV (Fig. 5a). Compared to
this tau phosphorylation the changes at other sites
were only minor. Analysis of the phosphorylation
relative to healthy control tissue in isocortical brain
regions (Fig. 5b-e) showed a progressive increase of
ThioS labeling in all regions with highest values in
the temporal cortex (Fig. 5b). Additionally, tau
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Fig. 3 Quantification of tau phosphorylation at pSer199 and pTyr18 in the cortex of AD cases. a Human pSer199 tau immunoreactive area in
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phosphorylation was severely increased at Thr231,
Ser199 and Tyr18. Tau phosphorylation at Thr231
was highest in the temporal cortex (Fig. 5b) while
phosphorylation at Ser199 and Tyr18 was highest in
the frontal cortex (Fig. 5c). Also in the isocortex tau
phosphorylation changes at other sites are only minor
compared to Thr231, Ser199 and Tyr18.
To validate results obtained by immunofluorescent la-
beling, Western blots of AD and control cases were per-
formed (Fig. 6a). Cases showing an increase in total tau
also showed a signal increase in all analyzed ptau resi-
dues. Furthermore, the majority of human cases with
strong ptau signals were clinically diagnosed with mild
dementia (case 6 and 12) or dementia (case 17, 18, 19,
Table 1), suggesting a correlation between phosphoryl-
ation and cognitive status. Even that tissue of some cases
was missing the quantification of Western blot results
shows an overall conformity compared to immunofluor-
escent labelings. Total tau by HT7 labeling (Fig. 6b),
pSer202/205 (Fig. 6c), and pSer199 (Fig. 6e) also showed
a late signal increase in Braak stage V/VI with only weak
signals in earlier Braak stages. Western blotting of
pThr231 (Fig. 6d) and pTyr18 (Fig. 6f ) also showed a
late signal increase in Braak stage V/VI while signals of
immunofluorescent labelings increased already in earlier
Braak stages (Fig. 2c and Fig. 3c).
Representative images of total tau (Fig. 7) and
pSer202/Thr205, pThr231, pSer199 and pTyr18 (Fig. 8)
immunofluorescent labelings in the transentorhinal cor-
tex of one case per Braak stage show the progressive in-
crease of these ptau sites.
In summary, our quantitative analysis of AD brain
tissue shows that a progressive increase of total tau
and ptau expression can be observed in the
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transentorhinal region and in most of the analyzed
isocortical regions. Staining of tissue with ThioS re-
sulted only in a weak signal in the transentorhinal
region and the occipital cortex. Labeling with anti-
bodies against different tau phosphorylation sites
showed that most ptau sites, namely pSer202/Thr205,
pThr231, pSer199, pTyr18 and pSer422 were highly
increased throughout the cortex at Braak stage V/VI.
Only tau phosphorylation at Thr231 and Thy18 was
already significantly increased at Braak stage III/IV.
By contrast, pSer396 tau and pSer262 tau are only
weakly expressed in all analyzed brain regions and
only minor progression was observed. When com-
paring tau phosphorylation in percent relative to
healthy controls, phosphorylation is specifically in-
creased at tau Thr231, Ser199 and Tyr18. These data
indicate that tau phosphorylation is a complex fea-
ture of AD progression, involving many but not all
potential phosphorylation sites.
Discussion
The current study was designed to analyze spatial pat-
terns of tau phosphorylation at multiple residues in
discrete anatomical regions during AD progression. Our
data revealed a very similar phosphorylation profile of
most of the analyzed ptau sites in the allo- and isocortex
while expression levels of phosphorylated tau at Tyr18
and Thr231 was distinguishable between Braak stages.
When normalized to controls, phosphorylation of tau at
Tyr18, Ser231 and also Ser199 was much more in-
creased at Braak stage V/VI compared to other residues,
suggesting a relevance of these sites for AD progression
and a crucial role in pathogenesis.
Since tau phosphorylation is a main characteristic of
AD progression, several groups have already analyzed
the temporal phosphorylation pattern of different tau
sites by histological methods. According to Luna-Munoz
and colleagues the phosphorylation of Thr231 tau is an
early event in the neuronal pathology of AD [27]. The
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temporal analysis of pSer202/Thr205 tau and pSer396
tau is very controversial. Simic and co-workers found
higher phosphorylation of Ser396 and Ser202/Thr205
tau in mild cognitive impairment (MCI) cases [38] sug-
gesting a parallel phosphorylation of both residues.
Temporal phosphorylation analyses by two other groups
contradict these results, while one group found an earl-
ier phosphorylation of pSer202/Thr205 tau [39], the
other reported an earlier phosphorylation of pSer396 tau
[30]. Zhou and colleagues performed dot blots and
ELISA analyses of a whole series of ptau sites of AD
medial temporal cortex samples and found mostly a
similar temporal phosphorylation pattern as shown here
for the entorhinal cortex. Tau phosphorylation of Ser396
for example, was a late event and only measurable in
Braak stage V and VI [46]. Dot blot analyses of AD lat-
eral temporal lobe samples by another group showed
that tau phosphorylation at Ser202/205 and Ser396
simultaneously increases with increasing Braak staging,
but also that they observe the increase already in Braak
stage III/IV compared to results shown here or by Zhou
and colleagues [20, 46]. By quantitatively analyzing ptau
sites in different brain regions of AD cases we found that
most analyzed ptau sites, pSer202/Thr205, pThr231,
pSer199, pTyr18 and pSer422, have a very similar allo-
and isocortical phosphorylation profile, suggesting that
pSer202/Thr205 tau analysis by AT8 antibody could be
replaced by any of these ptau sites when using this quan-
titative histological approach. For neuropathological as-
sessment of Braak stages ptau Ser202/Thr205
immunopositivity is scored semi-quantitatively and is re-
quired to be mild (+) in the transentorhinal cortex to as-
sign Braak stage I, while for stages higher than Braak
stage I, severity of ptau Ser202/Thr205 immunopositivity
in the transentorhinal cortex is not decisive as other
areas, e.g. entorhinal cortex, occipitotemporal gyrus,
Fig. 6 Quantification of total tau and tau phosphorylation in the transentorhinal cortex of AD cases by Western blotting. a: Western blots of total
tau, pThr231, pSer202/Thr205, pTyr18, and pSer199. GAPDH was used as loading control. Quantification of Western blot for (b) total tau by HT7
antibody, (c) pSer202/Thr205, (d) pThr231, (e) pSer199, and (f) pTyr18. All samples shown in (a) were used for quantification of (b-f). One way
ANOVA followed by Tukey’s multiple comparisons test. Mean + SEM. *p < 0.05; **p < 0.01; n.s.: not significant
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middle temporal gyrus, occipital cortex need to show at
least moderate (++) severity of immunopositivity [1].
Therefore our findings of a lack of a significant increase
of ptau Ser202/Thr205 immunopositivity in the transen-
torhinal cortex between Braak stages 0 to IV is not at
variance with neuropathological Braak staging. However,
pSer202/Thr205 immunopositivity does indeed increase
continuously in the transentorhinal cortex with increas-
ing Braak stages. In our study the difference is only sta-
tistically significant between Braak stages 0-IV and V/VI.
The phosphorylation of the analyzed tau sites starts in
the isocortical regions late at Braak stage V/VI and con-
sequently the analysis of the allocortical transentorhinal
region is preferable. Indeed, the quantitative analysis of
pTyr18 tau and pThr231 tau in the transentorhinal re-
gion shows a distinct progression between Braak stages
that might be caused by highly increased phosphoryl-
ation relative to control tissue that could also be ob-
served for pSer199 tau. Since phosphorylation of tau at
residues Tyr18 and Thr231 occurs earlier compared to
other sites, these phosphorylation sites might trigger dis-
ease progression and thus would represent an early
therapeutic target.
Western blot analyses of total tau and the most
prominent phosphorylation residues pSer202/Thr205,
pThr231, pSer199, and pTyr18 overall validated the
results obtained by immunofluorescent labeling. It has
to be mentioned that tissue of not all human cases
was available for blotting, so quantification and statis-
tical analyses should be understood as preliminary.
Blots for pSer202//Thr205 and pThr231 are not dir-
ectly comparable, since different antibodies as used
Fig. 7 Representative images of total tau labeling in the transentorhinal cortex grey matter of AD cases. Labeling of total tau using HT7 antibody
(a-d, a1-d1, a2-d2) and nuclei by DAPI staining (a-d, a1-d1,a3-d3). Autofluorescence is shown in white (a-d, a1-d1, a4-d4). Samples of healthy
control tissue (a-a4, case 2), Braak stage I/II (b-b4, case 8), Braak stage III/IV (c-c4, case 11) and Braak stage V/VI (d-d4, case 16) are shown. Scale
bar: 100 μm
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for immunofluorescent labelings had to be used for
methodical reasons.
AD is known to affect women with a higher preva-
lence, which is among other reasons caused by hormonal
differences. The higher frequency of AD cases in women
is reflected in this study by the fact that only tissue of
women was provided for Braak stage V/VI, while tissue
of earlier Braak stages was predominantly from men. Al-
though several in vitro and in vivo studies in rodents
suggest an impact of sex hormones (e.g. estrogens, pro-
gesterone and prolactin) and therefore gender on tau
phosphorylation, there are so far no studies in AD pa-
tients validating these results in humans (for review see
[33]). Future analyses of post mortem AD tissue and in
vivo imaging of AD patients should shed light on the
impact of gender on tau phosphorylation.
In addition to the severe increases in tau phosphoryl-
ation also the ThioS signal, that includes amyloid plaques,
was highly increased in several allo- and isocortical re-
gions. The ThioS signal increase partially already started
at Braak stage III/IV and thus earlier than the increase of
ptau. It has been shown that ptau residues, Tyr18, Thr231
and Ser199 can be phosphorylated by Aβ via different ki-
nases like Fyn [18, 35, 37, 42, 44, 45], GSK-3β [3, 23, 24]
or CDK5 [6, 25]. The activation of tau by Aβ is further
demonstrated to be involved in the early formation of
neurofibrillary tangles, synaptic loss, neurodegeneration as
well as cognitive deficits [2, 3, 11, 25] and thus in the de-
velopment of the most prominent AD pathologies. These
results were derived from AD cell and animal models but
our study might suggest a similar effect of Aβ on tau
phosphorylation at residues Tyr18, Thr231 and Ser199 in
the human disease. Further analyses are needed to validate
this hypothesis in humans. A valid tool to analyze such
events in vivo might be the use of Pittsburgh compound B
(PiB) analysis combined with tau tracer that are currently
under development [5, 17, 19, 36].
Isocortical tau pathology is only sparse at early Braak
stages I to IV and hence use of higher magnification and
modified image analysis parameters may be necessary to
reveal subtle changes in isocortical tau pathology at early
Braak stages. Additionally, co-labeling of different
markers to quantify ptau only in distinct areas or cell
populations combined with an increased number of in-
vestigated brain regions may be helpful to gain a better
understanding of earliest isocortical tau pathology. A
Fig. 8 Representative images of ptau labelings in the transentorhinal
cortex of control and AD cases. Labeling of pSer202/Thr205 (a),
pThr231 (b), pSer199 (c), and pTyr18 (d) are shown. Tissues were
additionally stained with DAPI to visualize nuclei. Autofluorescence is
shown in white. Dotted lines indicate areas shown in grey scale
images. Samples of healthy control tissue (case 2) and Braak stage V/
VI (case 16) are shown. Scale bar: 100 μm
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tissue microarray method that was developed recently
allows to examine over 35 brain regions on one slide
could be used for such purposes [43]. However, our
study investigated only five brain regions in a limited
number of cases and represents therefore proof of
principle. Our data need to be confirmed by including
more cases and assessing a higher number of brain
areas.
Conclusion
We show here for the first time the phosphorylation
profile of different tau sites in allocortical and isocortical
regions of human brains with tau pathology ranging
from Braak stages 0 to VI using quantitative
rater-independent immunofluorescent labeling. Our data
suggest that the profile of ptau in the isocortex is com-
parable between all of the analyzed ptau sites while ex-
pression levels of ptau at Thr231 and Tyr18 in the
transentorhinal region are distinguishable between Braak
stages combined with the highest tau phosphorylation
relative to controls at these sites and Ser199.
Additional file
Additional file 1: Online Source 9 Double labeling of pSer262 and
pSer202/Thr205 tau in the temporal cortex at Braak stage V/VI. Images show
different labeling pattern of pSer262 (arrows) and pS202 (white arrowheads)
as well as their overlay (yellow arrowheads) (a1) and single fluorescence
images (a2,3,4) of case 17. AF: autofluorescence. Scale bar: 20 μm. Online
Source 10 Example of measurement procedure of tau pSer262. Objects in
the unlabeled autofluorescence channel were detected by thresholding
(red in a1). The resulting mask images (a2) were then subtracted from tau
pSer262 images to remove autofluorescence (a3). The resulting images
were Edge+ filtered (a4) to facilitate threshold-based detection of tau
pSer262-positive objects (red outline in a5). These outlines were then loaded
onto the raw images to quantify original tau pSer262 signal (red outline in
a6). AF: autofluorescence. Scale bar: 20 μm. Online Source 11 Example of
detecting ThioS-positive amyloid-β but not NFTs. Image a displays the
co-labeling of ThioS (green) and HT7 (red), while images b and c,
respectively, show single channel images. ThioS shows intense labeling of
plaque-associated β-sheets (b, asterisk) whereas tangles are only weakly la-
beled (c, arrows) (c). A combination of threshold-based identification of
ThioS and size restriction (d‘, green rectangle) enables quantification of
ThioS+ plaque labeling (red highlighted) but not tangles (d). ThioS:
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